Dr. Stephen McSorley was recently awarded a National Institutes of Health grant to study “CD4 T cell responses to Chlamydia infection” through the National Institutes of Allergy and Infectious Diseases (R01AI103422). The CDC estimates that Chlamydia is one of the most prevalent bacterial infections in the US and causes upper reproductive tract pathology in a growing number of otherwise healthy young women. Unfortunately, women with untreated Chlamydia infection can develop serious pelvic inflammatory disease (PID), infertility, chronic pelvic pain, or suffer from ectopic pregnancy. Given the high incidence of infection and the potential for serious pathology, the current consensus among scientists and clinicians is that an effective Chlamydia vaccine is needed. In order for a vaccine to be generated, greater understanding of host immunity to Chlamydia infection in the upper reproductive tract is required. Our application will utilize new antigen-specific reagents that we have recently generated for the mouse model of genital Chlamydia infection. We will use these reagents to examine the heterogeneity of the CD4 T cell response to infection, the effect of antibiotic treatment on developing immunity, and boosting protective immunity to infection. For more information on Chlamydia and Dr. McSorley’s research program click here.